FDA-Drug2026-07-29Class IIMISBRANDING
Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
What this means
Major Pharmaceuticals is recalling levothyroxine sodium 50 mcg tablets (lot N02200, expiration 10/2026) because they do not contain the full labeled dose. Levothyroxine is a thyroid hormone replacement medication, and a subpotent tablet may not provide the intended therapeutic effect for patients who depend on consistent dosing.
- Check if you have levothyroxine sodium 50 mcg tablets from Major Pharmaceuticals with lot number N02200.
- Do not stop taking your levothyroxine without speaking to your doctor.
- Contact your pharmacist or doctor to confirm whether your supply is affected and discuss next steps.
The agency's original wording
Hazard
Subpotent Drug
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA.
Affected count
N/A
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Products
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6950-61
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0701-2026More Major Pharmaceuticals recalls
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
- FDA-Drug2026-07-29Major Pharmaceuticals Levothyroxine Sodium 112 mcg tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine 25 mcg tablets recalled for subpotency
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.